This episode is to advocates for a fundamental shift in how the biotechnology sector approaches licensing, moving it from a last-resort response to financial failure toward a proactive strategic objective. Current industry norms often force startups into distress-driven negotiations that strip away value and leverage, largely because public funding prioritizes scientific milestones over operational transferability. To correct this, I would suggests that licensing readiness—including standardized data packages and clear intellectual property boundaries—should be treated as a fundable capability supported by policy interventions. By utilizing standardized frameworks and public validation, innovators can reduce information gaps and improve value retention for founders and local ecosystems. Ultimately, the source argues that treating licensing as an intentional commercialization pathway rather than a "second best" outcome ensures more sustainable and resilient innovation.